Facts About Paniculoside I Revealed
All enrolled sufferers who been given at least just one dose of zosuquidar or placebo in the course of induction have been monitored for the event of adverse functions (439 people, 219 on zosuquidar and 210 on placebo). The commonest adverse occasions have been related to the period of extended and significant myelosuppression as is anticipated wit